Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression

11596,671

16/777630

January 30, 2020

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia B. In some embodiments, the present disclosure provides methods for dosing a hemophilia B patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor IX polypeptide.

Takeda Pharmaceutical Company Limited (Osaka, JP)

Takeda Pharmaceutical Company Limited (Osaka, JP)

1. A method for treating hemophilia B comprising intravenously infusing, to a human subject diagnosed with hemophilia B, a dose of from 2.5×10 11 to 2×10 12 adeno-associated virus (AAV) particles per kilogram body weight of the human subject, wherein the AAV particles comprise a Factor IX polynucleotide encoding a Factor IX protein, said Factor IX polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 17.

2. The method for treating hemophilia B according to claim 1 , wherein the intravenously infused dose is from 2.5×10 11 to 7.5×10 11 adeno-associated virus (AAV) particles per kilogram body weight of the human subject.

3. The method for treating hemophilia B according to claim 1 , wherein the intravenously infused dose is 5×10 11 adeno-associated virus (AAV) particles per kilogram body weight of the human subject.

4. The method for treating hemophilia B according to claim 1 , wherein the intravenously infused dose is from 7.5×10 11 to 1.25×10 12 adeno-associated virus (AAV) particles per kilogram body weight of the human subject.

5. The method for treating hemophilia B according to claim 1 , wherein the intravenously infused dose is 1×10 12 adeno-associated virus (AAV) particles per kilogram body weight of the human subject.

6. The method for treating hemophilia B according to claim 1 , wherein the Factor IX protein encoded by the Factor IX polynucleotide has the amino acid sequence of SEQ ID NO: 12.

7. A method for treating hemophilia B comprising intravenously infusing, to a human subject diagnosed with hemophilia B, a dose of from 2.5×10 11 to 2×10 12 adeno-associated virus (AAV) particles per kilogram body weight of the human subject, wherein the AAV particles comprise a Factor IX polynucleotide encoding a Factor IX protein, said Factor IX polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 13, SEO ID NO: 14, SEO ID NO: 15, and SEO ID NO: 16.

8. The method for treating hemophilia B according to claim 1 , wherein the AAV particles further comprise a liver-specific promoter element operably linked to the Factor IX polynucleotide.

9. The method for treating hemophilia B according to claim 8 , wherein the liver-specific promoter element comprises one copy of a promoter polynucleotide, said promoter polynucleotide comprising a nucleic acid sequence that is least 95% identical to SEQ ID NO: 39.

10. The method for treating hemophilia B according to claim 8 , wherein the liver-specific promoter element comprises three copies of a promoter polynucleotide, said promoter polynucleotide comprising a nucleic acid sequence that is least 95% identical to SEQ ID NO: 39.

11. The method for treating hemophilia B according to claim 9 , wherein said promoter polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 39.

12. The method for treating hemophilia B according to claim 1 , wherein the AAV particles further comprise an intron operatively linked to the Factor IX polynucleotide.

13. The method for treating hemophilia B according to claim 12 , wherein the intron comprises an MVM intron polynucleotide comprising a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 53.

14. The method for treating hemophilia B according to claim 12 , wherein said MVM intron polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 53.

15. The method for treating hemophilia B according to claim 12 , wherein said intron is positioned between a promoter element and the translation initiation site of the nucleotide sequence encoding a Factor IX polypeptide.

16. The method for treating hemophilia B according to claim 1 , wherein the AAV particles are serotype 8 adeno-associated virus (AAV-8) particles.

4797368 January 1989 Carter et al.
5139941 August 1992 Muzyczka et al.
5994136 November 1999 Naldini et al.
6013516 January 2000 Verma et al.
6531298 March 2003 Stafford et al.
8778870 July 2014 Madison et al.
10842853 November 2020 Horling
20180339026 November 2018 Horling
WO 2006036502 April 2006
WO 2009130208 October 2009
WO 2014064277 May 2014
WO-2016146757 September 2016
WO 2016146757 September 2016
WO 2016210170 December 2016
WO 2018217731 November 2018

Altschul et al. (1990) “Basic local alignment search tool,” Journal of molecular biology. 215(3):403-410. cited by applicant
Altschul et al. (1996) “Local alignment statistics,” Methods in enzymology. 266(2):460-480. cited by applicant
Altschul et al. (1997) “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic acids research. 25(17):3389-3402. cited by applicant
Asokan et al. (2012) “The AAV Vector Toolkit: Poised at the Clinical Crossroads,” Molecular Therapy. 20(4):699-708. cited by applicant
Bell et al. (2016) “Effects of self-complementarity, codon optimization, transgene, and dose on liver transduction with AAV8,” Human Gene Therapy Methods 27.6: 228-237. cited by applicant
Blomer et al. (1997) “Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector,” Journal of Virology. 71(9):6641-6649. cited by applicant
Brandstetter et al. (1995) “X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B,” Proceedings of the National Academy of Sciences 92.21: 9796-9800. cited by applicant
Chuah et al. (2012) “Platelet-directed gene therapy overcomes inhibitory antibodies to factor VIII,” Journal of Thrombosis and Haemostasis. 10(8):1566-1569. cited by applicant
Chuah et al. (2012) “Recent progress in gene therapy for hemophilia,” Human gene therapy. 23(6):557-565. cited by applicant
Chuah et al. (2013) “Gene therapy for hemophilia,” Journal of thrombosis and haemostasis. 11:99-110. cited by applicant
Chuah et al. (2014) “Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates,” Molecular Therapy. 22(9):1605-1613. cited by applicant
Collins et al. (2014) “Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial,” Blood 124.26: 3880-3886. cited by applicant
Cotten et al. (1992) “High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles,” Proc. Natl. Acad. Sci. 89:6094-6098. cited by applicant
Curiel (1994) “High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes,” Natural Immunity. 13:141-164. cited by applicant
Devereux et al. (1984) “A comprehensive set of sequence analysis programs for the VAX,” Nucleic acids research. 12(1):387-395. cited by applicant
Fath et al. (2011) “Multiparameter RNA and Codon Optimization: A Standardized Tool to Assess and Enhance Autologous Mammalian Gene Expression,” PLoS One. 6(3):1-14. cited by applicant
Faust et al. (2013) “CpG-depleted adeno-associated virus vectors evade immune detection,” The Journal of clinical investigation 123.7: 2994-3001. cited by applicant
Feng et al. (1987) “Progressive sequence alignment as a prerequisitetto correct phylogenetic trees,” Journal of molecular evolution. 25(4):351-360. cited by applicant
Gailani et al. (2014) “The mechanism underlying activation of factor IX by factor XIa,” Thrombosis research 133: S48-S51. cited by applicant
Gardinier-Garden et al. (1987) “CpG Islands in vertebrate genomes,” Journal of Molecular Biology. 196(2):261-282. cited by applicant
GenBank Database (Apr. 23, 2019) “Homo sapiens serpin family A member 1 (SERPINA1), transcript variant 1, mRNA”, Accession Reference No. NM_000295.4, 5 pages. cited by applicant
GenBank Database (Jun. 28, 2013) “haploid-with-alt-loci”, Accession Reference No. GCF 000001405.25, 4 pages. cited by applicant
GenBank Database (May 12, 2020) “coagulation factor IX isoform 1 preproprotein [Homo sapiens]”, Accession Reference No. NP_000124.1, 5 pages. cited by applicant
GenBank Database (May 7, 2020) “coagulation factor IX isoform 2 precursor [Homo sapiens]”, Accession Reference No. NP_001300842.1, 3 pages. cited by applicant
Giangrande (2016) “The future of hemophilia treatment: longer-acting factor concentrates versus gene therapy,” Seminars in thrombosis and hemostasis. 42(5):513-17. cited by applicant
Gray et al. (2011) “Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary Vectors,” Human Gene Therapy. 22:1143-1153. cited by applicant
Grote et al. (2005) “JCat: a novel tool to adapt codon usage of a target gene to its potential expression host,” Nucleic Acid Research. 33:W526-W531. cited by applicant
Haas et al. (1996) “Codon usage limitation in the expression of HIV-1 envelope glycoprotein,” Current Biology. 6(3):315-324. cited by applicant
Haut et al. (1998) “Intron definition is required for excision of the minute virus of mice small intron and definition of the upstream exon,” Journal of virology 72.3: 1834-1843. cited by applicant
Higgins et al. (1989) “Fast and sensitive multiple sequence alignments on a microcomputer,” Bioinformatics. 5(2):151-153. cited by applicant
High (2012) “The gene therapy journey for hemophilia: are we there yet?” Blood, The Journal of the American Society of Hematology. 120(23):4482-4487. cited by applicant
Hopfner et al. (1999) “Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding,” Structure 7.8: 989-996. cited by applicant
Hsieh et al. (2009) “Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma,” Cancer science. 100(3):537-545. cited by applicant
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2020/015934, dated Jul. 27, 2020, 16 pages. cited by applicant
Karlin et al. (1993) “Applications and statistics for multiple high-scoring segments in molecular sequences,” Proceedings of the National Academy of Sciences. 90(12):5873-5877. cited by applicant
Kay et al. (2000) “Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector,” Nature genetics 24.3: 257-261. cited by applicant
Kelleher et al. (1994) “Long-term episomal gene delivery in human lymphoid cells using human and avian adenoviral-assisted transfection,” Biotechniques. 17:1110-1117. cited by applicant
Kotin (2011) “Large-scale recombinant adeno-associated virus production,” Human molecular genetics. 20(R1):R2-R6. cited by applicant
Kudla et al. (2006) “High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells,” PLoS Biology. 4(6):0933-0942. cited by applicant
Lenting et al. (1998) “The life cycle of coagulation factor VIII in view of its structure and function,” Blood, The Journal of the American Society of Hematology. 92(11):3983-3996. cited by applicant
Lin et al. (1997) “A coagulation factor IX-deficient mouse model for human hemophilia B,” Blood, The Journal of the American Society of Hematology 90.10: 3962-3966. cited by applicant
Lindenbaum et al. (2004) “A mammalian artificial chromosome engineering system (ACE System) applicable to biopharmaceutical protein production, transgenesis and gene-based cell therapy,” Nucleic acids research 32.21: e172-e172 1-15. cited by applicant
Mann et al. (1983) “Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus,” Cell. 33(1):153-159. cited by applicant
Manno et al. (2006) “Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response,” Nature Medicine. 12:342-347. cited by applicant
Mátrai et al. (2010) “Preclinical and clinical progress in hemophilia gene therapy,” Current opinion in hematology. 17(5):387-392. cited by applicant
Mátrai et al. (2010) “Recent advances in lentiviral vector development and applications,” Molecular therapy. 18(3):477-490. cited by applicant
McCarty (2008) “Self-complementary AAV vectors; advances and applications,” Molecular Therapy 16.10: 1648-1656. cited by applicant
Mingozzi et al. (2007) “CD8+ T-cell responses to adeno-associated virus capsid in humans,” Nature medicine 13.4: 419-422. cited by applicant
Mirsafian et al. (2014) “A Comparative Analysis of Synonymous Codon Usage Bias Pattern in Human Albumin Superfamily,” Scientific World Journal. Article 639682, 7 pages. cited by applicant
Monahan et al. (2015) “Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial,” Human gene therapy 26.2:69-81. cited by applicant
Muzyczka (1992) “Use of adeno-associated virus as a general transduction vector for mammalian cells,” Current Topics Microbiology and Immunology. 158:97-129. cited by applicant
Nair et al. (2014) “Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy,” Blood, The Journal of the American Society of Hematology. 123(20):3195-3199. cited by applicant
Naldini et al. (1996) “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector,” Science. 272(5259):263-267. cited by applicant
Needleman et al. (1970) “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” Journal of molecular biology. 48(3):443-453. cited by applicant
Nicolas et al. (1988) “Retroviral vectors,” Vectors. A survey of molecular cloning vectors and their uses. 1:494-513. cited by applicant
Osooli et al. (2015) “Inhibitors in haemophilia: what have we learned from registries? A systematic review,” Journal of internal medicine 277.1: 1-15. cited by applicant
Pearson et al. (1988) “Improved tools for biological sequence comparison,” Proceedings of the National Academy of Sciences. 85(8):2444-2448. cited by applicant
Pechmann et al. (2013) “Evolutionary conservation of codon optimality reveals hidden signatures of cotranslational folding,” Nature structural & molecular biology 20.2: 237-243. cited by applicant
Pérez-Luz et al. (2010) “Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy,” Journal of Biomedicine and Biotechnology. Article ID 642804, 16 pages. cited by applicant
Saenko et al. (1999) “Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex,” Trends in cardiovascular medicine. 9(7):185-192. cited by applicant
Schuettrumpf et al. (2005) “Factor IX variants improve gene therapy efficacy for hemophilia B,” Blood 105.6: 2316-2323. cited by applicant
Sichler et al. (2003) “Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop,” Journal of Biological Chemistry 278.6: 4121-4126. cited by applicant
Simioni et al. (2009) “X-linked thrombophilia with a mutant factor IX (factor IX Padua),” New England Journal of Medicine 361.17: 1671-1675. cited by applicant
Smith et al. (1981) “Comparison of biosequences,” Advances in applied mathematics. 2(4):482-489. cited by applicant
Srivastava et al. (2013) “Guidelines for the management of hemophilia,” Haemophilia 19.1: e1-e47. cited by applicant
Tats et al. (2008) “Preferred and avoided codon pairs in three domains of life,” BMC Genomics. 9(463):1-15. cited by applicant
Temin (1986) “Retrovirus Vectors for Gene Transfer: Efficient Integration into and Expression of Exogenous DNA in Vertebrate Cell Genomes,” Gene Transfer. 1:149-188. cited by applicant
UniProt Database (Aug. 1, 1990) “Coagulation factor IX (FA9_MOUSE)”, Accession Reference No. P16294, 14 pages. cited by applicant
UniProt Database (Aug. 1, 1990) “Coagulation factor IX (FA9_RAT)”, Accession Reference No. P16296, 14 pages. cited by applicant
UniProt Database (Jul. 21, 1986) “Coagulation factor IX (FA9_BOVIN)”, Accession Reference No. P00741, 14 pages. cited by applicant
UniProt Database (Oct. 16, 2019) “RecName: Full=Coagulation factor IX; AltName: Full=Christmas factor; AltName: Full=Plasma thromboplastin component; Short=PTC; Contains: RecName: Full=Coagulation factor IXa light chain; Contains: RecName: Full=Coagulation factor IXa heavy chain; Flags: Precursor”, Accession Reference No. P00740.2, 36 pages. cited by applicant
UniProt Database (Sep. 9, 2020) “Report for CCDS14666.1”, Accession Reference No. CCDS14666.1, 2 pages. cited by applicant
Vandendriessche et al. (2012) “Clinical progress in gene therapy: sustained partial correction of the bleeding disorder in patients suffering from severe hemophilia B,” Human gene therapy. 23(1):4-6. cited by applicant
Vandendriessche et al. (2017) “Hemophilia gene therapy: ready for prime time?” Human gene therapy 28.11: 1013-1023. cited by applicant
Wu et al. (2008) “Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose,” Molecular Therapy 16.2: 280-289. cited by applicant
Zhang et al. (2009) “Factor VIII inhibitors: risk factors and methods for prevention and immune modulation,” Clinical reviews in allergy & immunology. 37(2):114-124. cited by applicant
Zufferey et al. (1997) “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo,” Nature Biotechnology. 15:871-875. cited by applicant
Lozier, Jay N. “Gene therapy. Factor IX Padua: them that have, give.” Blood vol. 120,23 (2012): 4452-3. doi:10.1182/blood-2012-09-452821. cited by applicant

edspgr.11596671